Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-25-057893
Filing Date
2025-06-25
Accepted
2025-06-25 17:16:53
Documents
117
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT ea0246623-20f_psyence.htm   iXBRL 20-F 1887094
2 CERTIFICATION ea024662301ex12-1_psyence.htm EX-12.1 11931
3 CERTIFICATION ea024662301ex12-2_psyence.htm EX-12.2 11957
4 CERTIFICATION ea024662301ex13-1_psyence.htm EX-13.1 5231
5 CONSENT OF MNP LLP ea024662301ex23-1_psyence.htm EX-23.1 3333
6 COMPENSATION CLAWBACK POLICY ea024662301ex97-1_psyence.htm EX-97.1 17358
7 GRAPHIC image_001.jpg GRAPHIC 63420
8 GRAPHIC image_002.jpg GRAPHIC 44242
9 GRAPHIC image_003.jpg GRAPHIC 78328
10 GRAPHIC image_004.jpg GRAPHIC 79245
11 GRAPHIC image_005.jpg GRAPHIC 66007
12 GRAPHIC image_006.jpg GRAPHIC 50673
13 GRAPHIC image_007.jpg GRAPHIC 91492
14 GRAPHIC image_008.jpg GRAPHIC 37346
15 GRAPHIC fin_001.jpg GRAPHIC 7153
16 GRAPHIC fin_002.jpg GRAPHIC 4220
17 GRAPHIC ex23-1_001.jpg GRAPHIC 7153
18 GRAPHIC ex23-1_002.jpg GRAPHIC 4973
  Complete submission text file 0001213900-25-057893.txt   9171798

Data Files

Seq Description Document Type Size
19 XBRL SCHEMA FILE pbm-20250331.xsd EX-101.SCH 121238
20 XBRL CALCULATION FILE pbm-20250331_cal.xml EX-101.CAL 45935
21 XBRL DEFINITION FILE pbm-20250331_def.xml EX-101.DEF 387940
22 XBRL LABEL FILE pbm-20250331_lab.xml EX-101.LAB 707139
23 XBRL PRESENTATION FILE pbm-20250331_pre.xml EX-101.PRE 397458
119 EXTRACTED XBRL INSTANCE DOCUMENT ea0246623-20f_psyence_htm.xml XML 865470
Mailing Address 121 RICHMOND STREET WEST PENTHOUSE SUITE 1300 TORONTO A6 M5H 2K1
Business Address 121 RICHMOND STREET WEST PENTHOUSE SUITE 1300 TORONTO A6 M5H 2K1 27744604171
PSYENCE BIOMEDICAL LTD. (Filer) CIK: 0001985062 (see all company filings)

EIN.: 000000000 | State of Incorp.: A6 | Fiscal Year End: 0331
Type: 20-F | Act: 34 | File No.: 001-41937 | Film No.: 251074496
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)